15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering 4D Molecular Therapeutics Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $21.00 to $38.00, a moderate spread. The average target of $31.50 sits 220% above the current $9.84. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.01 next quarter toward $-3.77 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to 4D Molecular Therapeutics Inc.
As of Jul, 6 of 6 firms rate FDMT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
FDMT EPS & revenue forecast
EPS · NEXT QUARTER
$-1.01
Range $-1.13 – $-0.83 · 8 analysts · +0% YoY
Next period, 8 analysts expect 4D Molecular Therapeutics Inc to earn $-1.01 a share (range $-1.13 – $-0.83), versus $-1.01 a year earlier. Full-year consensus is $-3.93, growing to $-3.77 the year after.
REVENUE · NEXT QUARTER
$2.7M
Range $0 – $7.5M · 8 analysts · +2919% YoY
Revenue is expected to reach $2.7M (range $0 – $7.5M), +2919.0% year-over-year. Full-year consensus is $11.6M, rising to $17.5M next year.
Top analysts covering 4D Molecular Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FDMT.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #51
Buy
$36.00+265.9% to target
Overall win rate
56%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #100
Buy
$26.00+164.2% to target
Overall win rate
44%
+ Follow
#3
TA
Tazeen Ahmad
B of A Securities · Rank #275
Buy
$40.00+306.5% to target
Overall win rate
41%
+ Follow
#4
Judah Frommer
Morgan Stanley
Hold
No targeton FDMT
Coverage
—
+ Follow
#5
LW
Lisa Walter
RBC Capital
Buy
$35.00+255.7% to target
Coverage
—
+ Follow
FDMT stock forecast FAQ
What is FDMT's average 12-month price target?+
The 6 analysts with a live target average $31.50 for 4D Molecular Therapeutics Inc over the next 12 months, ranging from a $38.00 high to a $21.00 low.
Is FDMT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for FDMT?+
The Street-high target is $38.00 (Roth Capital), and the Street-low is $21.00 (Jefferies). The average of all 6 active targets is $31.50.
How many Wall Street analysts cover FDMT?+
6 analysts have an active rating on 4D Molecular Therapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering FDMT?+
Among analysts who currently cover FDMT, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #51). Their current call is Buy with a $36.00 target.
What is 4D Molecular Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.01 per share (range $-1.13 – $-0.83) across 8 analysts. Full-year EPS is projected at $-3.93, rising to $-3.77 the following year.
How much revenue is 4D Molecular Therapeutics Inc expected to report next quarter?+
Consensus revenue is $2.7M (range $0 – $7.5M). Full-year revenue is projected at $11.6M, growing to $17.5M next year.
Have analysts been upgrading or downgrading FDMT lately?+
As of Jul, 6 of 6 firms rate FDMT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FDMT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
